This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
by Zacks Equity Research
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Medical Stocks Lagging Axonics (AXNX) This Year?
by Zacks Equity Research
Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
GlycoMimetics (GLYC) Upgraded to Buy: Here's Why
by Zacks Equity Research
GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes GlycoMimetics (GLYC) a New Buy Stock
by Zacks Equity Research
GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
Implied Volatility Surging for GlycoMimetics (GLYC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status
by Zacks Equity Research
GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.
GlycoMimetics (GLYC) in Focus: Stock Moves 8.1% Higher
by Zacks Equity Research
GlycoMimetics (GLYC) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry
by Zacks Equity Research
GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?
by Zacks Equity Research
Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.
GlycoMimetics Enters Oversold Territory
by Zacks Equity Research
GlycoMimetics, Inc. (GLYC) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
by Zacks Equity Research
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
by Zacks Equity Research
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Company News For Dec 13, 2017
by Zacks Equity Research
Companies in the news are: GLYC,KMG,PAY,PPHM
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%
by Zacks Equity Research
GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.
Why Earnings Season Could Be Great for GlycoMimetics (GLYC)
by Zacks Equity Research
GlycoMimetics' (GLYC) favorable Zacks Rank #3 (Hold) and positive ESP enhances its potential for a beat.
GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher
by Zacks Equity Research
GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares rise more than 9% on the day amid huge volumes.
Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
GlycoMimetics (GLYC) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?
by Zacks Equity Research
Investors in GlycoMimetics, Inc. (GLYC) need to pay close attention to the stock based on moves in the options market lately.
Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.